The nationwide experiment will initially include around 100,000 volunteers.
The US Food and Drug Administration will allow the personal genomics company to resume a disease-risk analysis.
February 20, 2015|
WIKIMEDIA, MAGGIE BARTLETT, NHGRIPersonal genomics testing firm 23andMe is easing back into health-prediction service after the US Food and Drug Administration (FDA) yesterday (February 19) gave its blessing for the company to market a test that would predict the risk of a rare disease called Bloom Syndrome. The FDA had put a stop to all of 23andMe’s health-prediction services in 2013 over concerns that the firm was overstepping its scientific authority.
“While this authorization is for a single carrier status test only, we are committed to providing US customers with health information once more tests have been through this process and we have a more comprehensive product offering,” CEO Anne Wojcicki wrote on the 23andMe blog.
As Forbes pointed out, “[t]he major news, however, is that the [FDA] also took this opportunity to announce that home-use genetic testing for other carrier genes will be exempt from premarketing approval, designating such tests as Class II diagnostics.”
According to the agency’s press release, “[t]his action creates the least burdensome regulatory path for autosomal recessive carrier screening tests with similar uses to enter the market.”